Cargando…
Unusual phylogenetic tree and circulating actionable ESR1 mutations in an aggressive luminal/HER2-low breast cancer: Case report
Under therapeutic pressure aggressive tumors evolve rapidly. Herein, a luminal B/HER2-low breast cancer was tracked for >3 years during a total of 6 largely unsuccessful therapy lines, from adjuvant to advanced settings. Targeted next generation sequencing (NGS) of the primary lesion, two metasta...
Autores principales: | Allegretti, Matteo, Barberi, Vittoria, Ercolani, Cristiana, Vidiri, Antonello, Giordani, Elena, Ciliberto, Gennaro, Giacomini, Patrizio, Fabi, Alessandra |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9874630/ https://www.ncbi.nlm.nih.gov/pubmed/36713585 http://dx.doi.org/10.3389/fonc.2022.1050452 |
Ejemplares similares
-
Liquid biopsy identifies actionable dynamic predictors of resistance to Trastuzumab Emtansine (T-DM1) in advanced HER2-positive breast cancer
por: Allegretti, Matteo, et al.
Publicado: (2021) -
Tearing down the walls: FDA approves next generation sequencing (NGS) assays for actionable cancer genomic aberrations
por: Allegretti, Matteo, et al.
Publicado: (2018) -
Esr1(+) cells in the ventromedial hypothalamus control female aggression
por: Hashikawa, Koichi, et al.
Publicado: (2017) -
Maintenance bevacizumab beyond first-line paclitaxel plus bevacizumab in patients with Her2-negative hormone receptor-positive metastatic breast cancer: efficacy in combination with hormonal therapy
por: Fabi, Alessandra, et al.
Publicado: (2012) -
Metastatic Melanoma: Liquid Biopsy as a New Precision Medicine Approach
por: Ricciardi, Elena, et al.
Publicado: (2023)